Literature DB >> 27836808

Mycoplasma genitalium and Trichomonas vaginalis in France: a point prevalence study in people screened for sexually transmitted diseases.

S Pereyre1, C Laurier Nadalié2, C Bébéar3.   

Abstract

OBJECTIVE: Mycoplasma genitalium and Trichomonas vaginalis are common causes of sexually transmitted infections, but limited prevalence data are available in France. We aimed to evaluate the prevalence of M. genitalium and T. vaginalis infections and to assess prevalence by gender, age, sample collection sites and clinical symptoms. A multicentre collection of specimens was intended to obtain a nationwide overview of the epidemiology.
METHODS: Between September 2014 and January 2015, a total of 2652 consecutive urogenital specimens submitted to the microbiology diagnostic departments of 16 French university hospitals for Chlamydia trachomatis and Neisseria gonorrhoeae detection were collected. M. genitalium and T. vaginalis prevalence were evaluated using a commercial real-time PCR kit. Clinical data from patients were anonymously collected.
RESULTS: T. vaginalis and M. genitalium prevalence were 1.7% (95% confidence interval 1.3-2.4) and 3.4% (95% confidence interval 2.8-4.2), respectively, and did not differ between gender or age groups, except M. genitalium prevalence between men and women in the 35- to 44-year age group (5.9 vs. 1.5%; p 0.03). M. genitalium prevalence was significantly higher in patients receiving care in sexually transmitted infection clinics, abortion centres, family planning clinics and prisons than in gynaecologic, obstetric and reproduction centres (4.0 vs. 1.7%, p 0.009). Among M. genitalium- and T. vaginalis-positive patients, 70.9 and 61.5% were asymptomatic, respectively.
CONCLUSIONS: The low T. vaginalis prevalence does not justify systematic screening for this organism in France. Conversely, selective screening for M. genitalium may be warranted in care settings that receive presumably high-risk sexual behaviour patients, regardless of symptoms.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  France; Mycoplasma genitalium; Prevalence; Screening; Trichomonas vaginalis

Mesh:

Year:  2016        PMID: 27836808     DOI: 10.1016/j.cmi.2016.10.028

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  12 in total

1.  Prevalence studies of M. genitalium and other sexually transmitted pathogens in high risk individuals indicate the need for comprehensive investigation of STIs for accurate diagnosis and effective treatment.

Authors:  George Panos
Journal:  Germs       Date:  2018-03-01

Review 2.  Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Authors:  Kawthar Bouchemal; Christian Bories; Philippe M Loiseau
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  STI with Mycoplasma genitalium-more common than Chlamydia trachomatis in patients attending youth clinics in Sweden.

Authors:  Peter Nolskog; Erik Backhaus; Salmir Nasic; Helena Enroth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-16       Impact factor: 3.267

4.  Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis.

Authors:  Ingibjörg Hilmarsdóttir; Eva Mjöll Arnardóttir; Elísabet Reykdal Jóhannesdóttir; Freyja Valsdóttir; Daniel Golparian; Ronza Hadad; Hannes Bjarki Vigfússon; Magnus Unemo
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

5.  High Rates of Asymptomatic Mycoplasma genitalium Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study.

Authors:  Alexander Ring; Suraj Balakrishna; Frank Imkamp; Sara Burkard; Flurina Triet; Flurina Brunschweiler; Christina Grube; Rebecca Bodmer; Roger D Kouyos; Huldrych F Günthard; Dominique L Braun
Journal:  Open Forum Infect Dis       Date:  2022-04-27       Impact factor: 4.423

Review 6.  Molecular Diagnostics Update for the Emerging (If Not Already Widespread) Sexually Transmitted Infection Agent Mycoplasma genitalium: Just About Ready for Prime Time.

Authors:  Erik Munson
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

7.  Prevalence of Mycoplasma genitalium and other sexually-transmitted pathogens among high-risk individuals in Greece.

Authors:  Paraskevi Chra; Joseph Papaparaskevas; Eleni Papadogeorgaki; George Panos; Michalis Leontsinidis; George Arsenis; Athanassios Tsakris
Journal:  Germs       Date:  2018-03-01

8.  Performance of syndromic management for the detection and treatment of genital Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis among women attending antenatal, well woman and sexual health clinics in Papua New Guinea: a cross-sectional study.

Authors:  Lisa M Vallely; Pamela Toliman; Claire Ryan; Glennis Rai; Johanna Wapling; Josephine Gabuzzi; Joyce Allen; Christine Opa; Gloria Munnull; Petronia Kaima; Benny Kombuk; Antonia Kumbia; Zure Kombati; Greg Law; Angela Kelly-Hanku; Handan Wand; Peter M Siba; Glen D L Mola; John M Kaldor; Andrew J Vallely
Journal:  BMJ Open       Date:  2017-12-29       Impact factor: 2.692

9.  French Prospective Clinical Evaluation of the Aptima Mycoplasma genitalium CE-IVD Assay and Macrolide Resistance Detection Using Three Distinct Assays.

Authors:  Chloé Le Roy; Sabine Pereyre; Nadège Hénin; Cécile Bébéar
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

10.  Evaluation of a Commercial Multiplex Quantitative PCR (qPCR) Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance-Associated Mutations in Clinical Specimens.

Authors:  Chloé Le Roy; Nadège Hénin; Cécile Bébéar; Sabine Pereyre
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.